Skip to content
OpenCapital
Get started

Kodiak Sciences Inc KOD Enterprise value

Enterprise value at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
HRO
HarrowHROW
$1.53B+13.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.86B+85.0%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.26B+40.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$1.77B+1,855%
Vera Therapeutics logo
Vera TherapeuticsVERA
$2.83B+85.0%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

$2.3Bmarket cap+$56.0Mtotal debt−$169.5Mcash and equivalents=$2.21B

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's enterprise value?
Kodiak Sciences Inc (KOD) reported enterprise value of $2.21B in Q1 2026.
How has Kodiak Sciences Inc's enterprise value changed year-over-year?
Kodiak Sciences Inc's enterprise value increased by 2797.5% year-over-year, from $76.4M to $2.21B.
What is the long-term trend for Kodiak Sciences Inc's enterprise value?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's enterprise value has grown at a -25.4% compound annual growth rate (CAGR), from $6.73B to $1.56B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.